Nurtec prescribing information?

Nurtec ODT is rimegepant. It’s a CGRP receptor antagonist approved for both acute treatment and preventive treatment of migraine in adults. Here’s a concise, high-level summary of the prescribing information. If you want the exact, full label text, I can point you to the official FDA/DailyMed labeling.

Key points at a glance
- Indications
- Acute treatment of migraine with or without aura in adults
- Preventive treatment of migraine in adults (dose and duration per label)
- Mechanism of action
- Calcitonin gene-related peptide (CGRP) receptor antagonist (gepant)
- Formulation
- Oral dissolving tablet (ODT)
- Administration (general guidance)
- Taken as directed for acute treatment; tablet dissolves on the tongue
- Can be taken with or without food
- Do not chew the tablet
- Contraindications
- Hypersensitivity to rimegepant or any component of the formulation
- Warnings and precautions (high level)
- Monitor for adverse reactions; be aware of potential drug interactions
- Rimegepant is metabolized by CYP enzymes; interactions with strong CYP3A4 inhibitors/inducers may occur
- Common adverse reactions
- The label lists adverse events observed in trials; refer to the official label for a complete list and frequencies
- Drug interactions (conceptual)
- Interacts with enzymes (CYP3A4, possibly CYP2C9); strong inhibitors or inducers can alter rimegepant levels
- If you’re taking other migraine therapies or liver/metabolic medications, check interactions
- Use in special populations
- Pregnant or breastfeeding: consult healthcare provider
- Pediatric use: approval currently for adults (as of the labeling)
- Use with liver impairment: follow label guidance
- Storage
- Store as directed in the label (usually at room temperature, protect from moisture)

Where to find the official labeling
- FDA labeling (full, official) and a machine-readable label
- DailyMed entry for Nurtec (rimegepant), which contains the current approved labeling text

Would you like me to fetch the latest official label text and provide a section-by-section summary (Indications, Dosing, Contraindications, Warnings, Adverse Reactions, Drug Interactions, Use in Special Populations), or tailor the summary for patients vs. clinicians?